AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
suxamethonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 2489 | 306-40-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 20, 1952 | FDA | SANDOZ |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 693.41 | 41.97 | 191 | 5295 | 31426 | 90591535 |
| Cardiac arrest | 255.09 | 41.97 | 125 | 5361 | 104810 | 90518151 |
| Hyperthermia malignant | 253.79 | 41.97 | 47 | 5439 | 1251 | 90621710 |
| Hypotension | 251.60 | 41.97 | 185 | 5301 | 325212 | 90297749 |
| Anaphylactic reaction | 188.17 | 41.97 | 96 | 5390 | 87428 | 90535533 |
| Exposure during pregnancy | 180.36 | 41.97 | 134 | 5352 | 238276 | 90384685 |
| Maternal exposure during delivery | 176.59 | 41.97 | 42 | 5444 | 3804 | 90619157 |
| Diabetes insipidus | 162.79 | 41.97 | 38 | 5448 | 3174 | 90619787 |
| Maternal exposure during pregnancy | 134.16 | 41.97 | 135 | 5351 | 359928 | 90263033 |
| Bronchospasm | 132.09 | 41.97 | 49 | 5437 | 20660 | 90602301 |
| Neuromuscular block prolonged | 129.94 | 41.97 | 24 | 5462 | 628 | 90622333 |
| Renal ischaemia | 129.43 | 41.97 | 24 | 5462 | 642 | 90622319 |
| Tracheal deviation | 128.92 | 41.97 | 21 | 5465 | 255 | 90622706 |
| Apnoea | 126.52 | 41.97 | 39 | 5447 | 9375 | 90613586 |
| PCO2 increased | 124.69 | 41.97 | 26 | 5460 | 1287 | 90621674 |
| Phrenic nerve paralysis | 123.94 | 41.97 | 21 | 5465 | 329 | 90622632 |
| Status epilepticus | 110.68 | 41.97 | 42 | 5444 | 18832 | 90604129 |
| Ventricular tachycardia | 103.08 | 41.97 | 43 | 5443 | 24665 | 90598296 |
| Blood pH decreased | 102.32 | 41.97 | 25 | 5461 | 2533 | 90620428 |
| PO2 increased | 98.38 | 41.97 | 20 | 5466 | 872 | 90622089 |
| Delayed recovery from anaesthesia | 95.51 | 41.97 | 20 | 5466 | 1010 | 90621951 |
| Rhabdomyolysis | 95.09 | 41.97 | 51 | 5435 | 51205 | 90571756 |
| Oxygen saturation abnormal | 94.10 | 41.97 | 26 | 5460 | 4262 | 90618699 |
| Blood bicarbonate decreased | 92.52 | 41.97 | 24 | 5462 | 3095 | 90619866 |
| Bradycardia | 91.08 | 41.97 | 59 | 5427 | 83788 | 90539173 |
| Seizure | 87.50 | 41.97 | 73 | 5413 | 152556 | 90470405 |
| Left ventricular dysfunction | 87.29 | 41.97 | 33 | 5453 | 14636 | 90608325 |
| Drug interaction | 87.26 | 41.97 | 95 | 5391 | 276358 | 90346603 |
| Foetal death | 86.21 | 41.97 | 36 | 5450 | 20687 | 90602274 |
| Foetal exposure during pregnancy | 83.20 | 41.97 | 44 | 5442 | 42931 | 90580030 |
| Pseudocholinesterase deficiency | 78.77 | 41.97 | 12 | 5474 | 91 | 90622870 |
| Premature delivery | 75.92 | 41.97 | 40 | 5446 | 38722 | 90584239 |
| Premature baby | 73.32 | 41.97 | 34 | 5452 | 25043 | 90597918 |
| Anaesthetic complication neurological | 66.47 | 41.97 | 14 | 5472 | 727 | 90622234 |
| Serotonin syndrome | 65.52 | 41.97 | 36 | 5450 | 37851 | 90585110 |
| Hyperkalaemia | 63.93 | 41.97 | 43 | 5443 | 64921 | 90558040 |
| Electroencephalogram abnormal | 63.72 | 41.97 | 19 | 5467 | 4077 | 90618884 |
| Unwanted awareness during anaesthesia | 62.21 | 41.97 | 12 | 5474 | 398 | 90622563 |
| Renal impairment | 59.49 | 41.97 | 50 | 5436 | 105371 | 90517590 |
| Anaesthetic complication | 58.97 | 41.97 | 16 | 5470 | 2449 | 90620512 |
| Paralysis | 58.23 | 41.97 | 23 | 5463 | 11455 | 90611506 |
| Schizencephaly | 58.03 | 41.97 | 11 | 5475 | 332 | 90622629 |
| Cerebral haemorrhage foetal | 57.87 | 41.97 | 11 | 5475 | 337 | 90622624 |
| Blood magnesium decreased | 54.50 | 41.97 | 24 | 5462 | 15669 | 90607292 |
| Patent ductus arteriosus | 53.32 | 41.97 | 17 | 5469 | 4552 | 90618409 |
| Premature labour | 51.50 | 41.97 | 22 | 5464 | 13354 | 90609607 |
| Normal newborn | 51.17 | 41.97 | 26 | 5460 | 23336 | 90599625 |
| Phaeochromocytoma crisis | 50.97 | 41.97 | 10 | 5476 | 363 | 90622598 |
| Hypoxia | 50.74 | 41.97 | 39 | 5447 | 72360 | 90550601 |
| Circulatory collapse | 49.60 | 41.97 | 26 | 5460 | 24878 | 90598083 |
| Clonus | 49.48 | 41.97 | 17 | 5469 | 5733 | 90617228 |
| Ventricular fibrillation | 47.23 | 41.97 | 21 | 5465 | 14023 | 90608938 |
| Encephalopathy | 46.29 | 41.97 | 31 | 5455 | 46413 | 90576548 |
| Pulseless electrical activity | 45.66 | 41.97 | 18 | 5468 | 8914 | 90614047 |
| Kounis syndrome | 44.79 | 41.97 | 13 | 5473 | 2540 | 90620421 |
| Unresponsive to stimuli | 44.26 | 41.97 | 28 | 5458 | 38093 | 90584868 |
| Diarrhoea | 42.49 | 41.97 | 4 | 5482 | 939186 | 89683775 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperthermia malignant | 487.87 | 31.94 | 98 | 3942 | 2560 | 42614735 |
| Anaphylactic shock | 338.33 | 31.94 | 114 | 3926 | 23403 | 42593892 |
| Cardiac arrest | 193.26 | 31.94 | 123 | 3917 | 109197 | 42508098 |
| Serotonin syndrome | 160.98 | 31.94 | 68 | 3972 | 25777 | 42591518 |
| Anaphylactic reaction | 148.56 | 31.94 | 75 | 3965 | 42668 | 42574627 |
| Rhabdomyolysis | 116.16 | 31.94 | 79 | 3961 | 77940 | 42539355 |
| Neuromuscular block prolonged | 114.46 | 31.94 | 23 | 4017 | 596 | 42616699 |
| Pseudocholinesterase deficiency | 97.63 | 31.94 | 15 | 4025 | 72 | 42617223 |
| Hypotension | 91.81 | 31.94 | 117 | 3923 | 257514 | 42359781 |
| Electrocardiogram ST segment elevation | 85.98 | 31.94 | 29 | 4011 | 5910 | 42611385 |
| Procedural hypotension | 71.30 | 31.94 | 17 | 4023 | 986 | 42616309 |
| Anaesthetic complication | 64.99 | 31.94 | 17 | 4023 | 1440 | 42615855 |
| Respiratory acidosis | 61.52 | 31.94 | 23 | 4017 | 6308 | 42610987 |
| Drug interaction | 60.65 | 31.94 | 98 | 3942 | 266901 | 42350394 |
| Bradycardia | 60.64 | 31.94 | 56 | 3984 | 85428 | 42531867 |
| Bronchospasm | 57.89 | 31.94 | 27 | 4013 | 12858 | 42604437 |
| Seizure like phenomena | 54.76 | 31.94 | 14 | 4026 | 1083 | 42616212 |
| Apnoea | 53.43 | 31.94 | 22 | 4018 | 7781 | 42609514 |
| Ventricular tachycardia | 48.26 | 31.94 | 32 | 4008 | 30128 | 42587167 |
| Metabolic acidosis | 46.84 | 31.94 | 39 | 4001 | 51819 | 42565476 |
| Muscle rigidity | 44.26 | 31.94 | 22 | 4018 | 12037 | 42605258 |
| Therapeutic product effect prolonged | 42.33 | 31.94 | 9 | 4031 | 309 | 42616986 |
| Paralysis | 42.06 | 31.94 | 18 | 4022 | 7002 | 42610293 |
| Pulseless electrical activity | 42.03 | 31.94 | 19 | 4021 | 8418 | 42608877 |
| Hyporesponsive to stimuli | 41.03 | 31.94 | 12 | 4028 | 1534 | 42615761 |
| Tachycardia | 40.74 | 31.94 | 49 | 3991 | 101038 | 42516257 |
| Cardio-respiratory arrest | 40.74 | 31.94 | 38 | 4002 | 58598 | 42558697 |
| Hypoxia | 38.74 | 31.94 | 40 | 4000 | 69746 | 42547549 |
| Pigment nephropathy | 38.21 | 31.94 | 6 | 4034 | 34 | 42617261 |
| Stress cardiomyopathy | 37.94 | 31.94 | 13 | 4027 | 2772 | 42614523 |
| Trismus | 37.50 | 31.94 | 13 | 4027 | 2871 | 42614424 |
| Hyperkalaemia | 37.43 | 31.94 | 42 | 3998 | 80416 | 42536879 |
| Blood creatine phosphokinase increased | 36.84 | 31.94 | 33 | 4007 | 48305 | 42568990 |
| Pseudomonal sepsis | 36.10 | 31.94 | 14 | 4026 | 4235 | 42613060 |
| Neuromuscular blockade | 35.90 | 31.94 | 8 | 4032 | 343 | 42616952 |
| Haemodynamic instability | 34.87 | 31.94 | 19 | 4021 | 12538 | 42604757 |
| Muscle contractions involuntary | 33.69 | 31.94 | 11 | 4029 | 2023 | 42615272 |
| Diarrhoea | 32.85 | 31.94 | 3 | 4037 | 460846 | 42156449 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 1006.50 | 30.99 | 306 | 8976 | 51240 | 110528777 |
| Hyperthermia malignant | 709.56 | 30.99 | 140 | 9142 | 3760 | 110576257 |
| Cardiac arrest | 424.28 | 30.99 | 241 | 9041 | 196512 | 110383505 |
| Anaphylactic reaction | 332.59 | 30.99 | 171 | 9111 | 114129 | 110465888 |
| Hypotension | 312.02 | 30.99 | 294 | 8988 | 523555 | 110056462 |
| Neuromuscular block prolonged | 240.26 | 30.99 | 47 | 9235 | 1200 | 110578817 |
| Rhabdomyolysis | 200.22 | 30.99 | 125 | 9157 | 120276 | 110459741 |
| Serotonin syndrome | 187.84 | 30.99 | 94 | 9188 | 59059 | 110520958 |
| Pseudocholinesterase deficiency | 182.08 | 30.99 | 29 | 9253 | 210 | 110579807 |
| Bronchospasm | 181.78 | 30.99 | 75 | 9207 | 30164 | 110549853 |
| Maternal exposure during delivery | 161.12 | 30.99 | 41 | 9241 | 3524 | 110576493 |
| Bradycardia | 148.85 | 30.99 | 115 | 9167 | 155402 | 110424615 |
| Ventricular tachycardia | 145.70 | 30.99 | 75 | 9207 | 49934 | 110530083 |
| Exposure during pregnancy | 143.47 | 30.99 | 116 | 9166 | 167308 | 110412709 |
| Apnoea | 140.12 | 30.99 | 50 | 9232 | 13589 | 110566428 |
| Drug interaction | 130.98 | 30.99 | 184 | 9098 | 499999 | 110080018 |
| Diabetes insipidus | 123.47 | 30.99 | 38 | 9244 | 6532 | 110573485 |
| Delayed recovery from anaesthesia | 122.75 | 30.99 | 30 | 9252 | 2185 | 110577832 |
| Anaesthetic complication | 122.19 | 30.99 | 33 | 9249 | 3573 | 110576444 |
| Maternal exposure during pregnancy | 121.20 | 30.99 | 127 | 9155 | 254756 | 110325261 |
| PCO2 increased | 120.95 | 30.99 | 29 | 9253 | 1948 | 110578069 |
| Tracheal deviation | 120.44 | 30.99 | 21 | 9261 | 277 | 110579740 |
| Phrenic nerve paralysis | 106.23 | 30.99 | 21 | 9261 | 566 | 110579451 |
| Renal ischaemia | 96.57 | 30.99 | 25 | 9257 | 2298 | 110577719 |
| Respiratory acidosis | 95.81 | 30.99 | 38 | 9244 | 13788 | 110566229 |
| Blood pH decreased | 91.97 | 30.99 | 28 | 9254 | 4641 | 110575376 |
| Paralysis | 91.37 | 30.99 | 38 | 9244 | 15562 | 110564455 |
| Electrocardiogram ST segment elevation | 88.14 | 30.99 | 32 | 9250 | 9128 | 110570889 |
| Status epilepticus | 88.04 | 30.99 | 46 | 9236 | 31525 | 110548492 |
| PO2 increased | 85.80 | 30.99 | 21 | 9261 | 1538 | 110578479 |
| Hypoxia | 84.85 | 30.99 | 77 | 9205 | 129438 | 110450579 |
| Foetal death | 83.70 | 30.99 | 36 | 9246 | 16009 | 110564008 |
| Anaesthetic complication neurological | 83.51 | 30.99 | 19 | 9263 | 1014 | 110579003 |
| Oxygen saturation abnormal | 82.83 | 30.99 | 27 | 9255 | 5584 | 110574433 |
| Tachycardia | 80.37 | 30.99 | 97 | 9185 | 226548 | 110353469 |
| Pulseless electrical activity | 78.97 | 30.99 | 35 | 9247 | 16722 | 110563295 |
| Diarrhoea | 76.33 | 30.99 | 5 | 9277 | 1139500 | 109440517 |
| Cardio-respiratory arrest | 74.17 | 30.99 | 68 | 9214 | 115768 | 110464249 |
| Left ventricular dysfunction | 73.52 | 30.99 | 37 | 9245 | 23456 | 110556561 |
| Therapeutic product effect prolonged | 73.38 | 30.99 | 16 | 9266 | 702 | 110579315 |
| Procedural hypotension | 71.34 | 30.99 | 20 | 9262 | 2485 | 110577532 |
| Stress cardiomyopathy | 71.24 | 30.99 | 32 | 9250 | 15774 | 110564243 |
| Seizure | 70.91 | 30.99 | 90 | 9192 | 221095 | 110358922 |
| Blood bicarbonate decreased | 70.08 | 30.99 | 24 | 9258 | 5773 | 110574244 |
| Hyperkalaemia | 68.64 | 30.99 | 70 | 9212 | 135726 | 110444291 |
| Premature delivery | 64.30 | 30.99 | 37 | 9245 | 30595 | 110549422 |
| Neuromuscular blockade | 61.85 | 30.99 | 14 | 9268 | 730 | 110579287 |
| Fatigue | 60.67 | 30.99 | 14 | 9268 | 1215944 | 109364073 |
| Metabolic acidosis | 58.92 | 30.99 | 56 | 9226 | 99688 | 110480329 |
| Electroencephalogram abnormal | 57.28 | 30.99 | 21 | 9261 | 6152 | 110573865 |
| Ventricular fibrillation | 56.51 | 30.99 | 38 | 9244 | 41275 | 110538742 |
| Muscle rigidity | 55.77 | 30.99 | 31 | 9251 | 24000 | 110556017 |
| Haemodynamic instability | 54.41 | 30.99 | 30 | 9252 | 22858 | 110557159 |
| Drug ineffective | 54.33 | 30.99 | 261 | 9021 | 1520279 | 109059738 |
| Premature labour | 52.55 | 30.99 | 22 | 9260 | 9150 | 110570867 |
| Unwanted awareness during anaesthesia | 52.51 | 30.99 | 11 | 9271 | 398 | 110579619 |
| Nausea | 51.18 | 30.99 | 20 | 9262 | 1235670 | 109344347 |
| Circulatory collapse | 50.47 | 30.99 | 36 | 9246 | 42957 | 110537060 |
| Clonus | 50.25 | 30.99 | 21 | 9261 | 8695 | 110571322 |
| Post procedural complication | 50.16 | 30.99 | 30 | 9252 | 26628 | 110553389 |
| Unresponsive to stimuli | 49.94 | 30.99 | 42 | 9240 | 63748 | 110516269 |
| Trismus | 48.75 | 30.99 | 19 | 9263 | 6577 | 110573440 |
| Fear | 48.63 | 30.99 | 28 | 9254 | 23165 | 110556852 |
| Normal newborn | 47.43 | 30.99 | 27 | 9255 | 21869 | 110558148 |
| Allergy test negative | 46.76 | 30.99 | 10 | 9272 | 400 | 110579617 |
| Negative pressure pulmonary oedema | 46.64 | 30.99 | 11 | 9271 | 688 | 110579329 |
| Seizure like phenomena | 45.36 | 30.99 | 14 | 9268 | 2427 | 110577590 |
| Hypercapnia | 45.27 | 30.99 | 21 | 9261 | 11138 | 110568879 |
| Phaeochromocytoma crisis | 44.51 | 30.99 | 10 | 9272 | 504 | 110579513 |
| Blood magnesium decreased | 44.24 | 30.99 | 25 | 9257 | 19971 | 110560046 |
| Anaphylactoid shock | 42.88 | 30.99 | 11 | 9271 | 975 | 110579042 |
| Arthralgia | 40.80 | 30.99 | 8 | 9274 | 779624 | 109800393 |
| Laryngospasm | 40.08 | 30.99 | 15 | 9267 | 4653 | 110575364 |
| Anhedonia | 38.82 | 30.99 | 21 | 9261 | 15407 | 110564610 |
| Headache | 38.64 | 30.99 | 13 | 9269 | 882364 | 109697653 |
| Hypotonia | 38.42 | 30.99 | 21 | 9261 | 15724 | 110564293 |
| Emotional distress | 38.17 | 30.99 | 31 | 9251 | 44816 | 110535201 |
| Muscle contractions involuntary | 37.14 | 30.99 | 14 | 9268 | 4430 | 110575587 |
| Generalised tonic-clonic seizure | 36.73 | 30.99 | 33 | 9249 | 54647 | 110525370 |
| Renal impairment | 35.92 | 30.99 | 60 | 9222 | 188385 | 110391632 |
| Symptom masked | 35.77 | 30.99 | 11 | 9271 | 1884 | 110578133 |
| Pigment nephropathy | 35.01 | 30.99 | 6 | 9276 | 71 | 110579946 |
| Blood creatine phosphokinase increased | 33.89 | 30.99 | 36 | 9246 | 73041 | 110506976 |
| Tryptase increased | 33.69 | 30.99 | 9 | 9273 | 934 | 110579083 |
| Respiratory depression | 33.48 | 30.99 | 25 | 9257 | 31976 | 110548041 |
| Blood calcium decreased | 33.11 | 30.99 | 26 | 9256 | 35819 | 110544198 |
| Bradyarrhythmia | 32.23 | 30.99 | 13 | 9269 | 4921 | 110575096 |
| Myoclonic epilepsy | 31.98 | 30.99 | 11 | 9271 | 2680 | 110577337 |
| Airway complication of anaesthesia | 31.56 | 30.99 | 8 | 9274 | 676 | 110579341 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03AB01 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D009467 | Neuromuscular Depolarizing Agents |
| FDA EPC | N0000175719 | Depolarizing Neuromuscular Blocker |
| FDA PE | N0000175733 | Neuromuscular Depolarizing Blockade |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
| CHEBI has role | CHEBI:51372 | neuromuscular agent |
| CHEBI has role | CHEBI:88188 | drug allergen |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Muscle relaxation, function | indication | 11977004 | |
| General anesthesia | indication | 50697003 | |
| Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Hypocalcemia | contraindication | 5291005 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Infectious disease | contraindication | 40733004 | |
| Myxedema | contraindication | 43153006 | DOID:11634 |
| Hypokalemia | contraindication | 43339004 | |
| Burn injury | contraindication | 48333001 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Muscular dystrophy | contraindication | 73297009 | DOID:9884 |
| Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
| Third degree burn injury | contraindication | 80247002 | |
| Spinal cord injury | contraindication | 90584004 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Fracture of bone | contraindication | 125605004 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Spasticity | contraindication | 221360009 | |
| Rhabdomyolysis | contraindication | 240131006 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Injury of eye region | contraindication | 282752000 | |
| Deficiency of cholinesterase | contraindication | 360607009 | |
| At risk for aspiration | contraindication | 371736008 | |
| Primary malignant neoplasm | contraindication | 372087000 | |
| Surgical procedure on eye proper | contraindication | 373353005 | |
| Fever | contraindication | 386661006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Malignant hyperthermia | contraindication | 405501007 | |
| Cardiac arrest | contraindication | 410429000 | DOID:0060319 |
| Traumatic injury | contraindication | 417746004 | |
| Cardiac Decompensation | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscle-type nicotinic acetylcholine receptor | Ion channel | AGONIST | CHEMBL | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 4.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017730 | VUID |
| N0000178917 | NUI |
| D00766 | KEGG_DRUG |
| 71-27-2 | SECONDARY_CAS_RN |
| 4017730 | VANDF |
| 4019935 | VANDF |
| C0038627 | UMLSCUI |
| CHEBI:45652 | CHEBI |
| SCK | PDB_CHEM_ID |
| CHEMBL703 | ChEMBL_ID |
| CHEMBL983 | ChEMBL_ID |
| DB00202 | DRUGBANK_ID |
| 5314 | PUBCHEM_CID |
| 10154 | RXNORM |
| 1940 | MMSL |
| 5517 | MMSL |
| d00376 | MMSL |
| 001676 | NDDF |
| 005590 | NDDF |
| 372724004 | SNOMEDCT_US |
| 3822002 | SNOMEDCT_US |
| 58907007 | SNOMEDCT_US |
| D013390 | MESH_DESCRIPTOR_UI |
| 4004 | IUPHAR_LIGAND_ID |
| 26 | INN_ID |
| J2R869A8YF | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9983 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9983 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
| QUELICIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 27 sections |
| QUELICIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6970 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 27 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3411 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 24 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9053 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 24 sections |
| Succinylcholine Chloride | Human Prescription Drug Label | 1 | 14445-407 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-981 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-371 | INJECTION | 200 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-666 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 24 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1353 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1525 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1526 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | Human prescription drug label | 1 | 52817-734 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 22 sections |
| SUCCINYLCHOLINE CHLORIDE | Human Prescription Drug Label | 1 | 55150-315 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 25 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-943 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-232 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-232 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
| Succinylcholine Chloride | Human Prescription Drug Label | 1 | 68083-450 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 25 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-301 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-783 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1581 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 25 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4409 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1377 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70756-613 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1352 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 2 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-719 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-719 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |